Analytical Data
-
基因名
MYO3A
- Application
-
别名
MYO3A; Myosin-IIIa; EC 2.7.11.1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NEV4
-
表达区间
1-247 aa
-
氨基酸序列
MFPLIGKTIIFDNFPDPSDTWEITETIGKGTYGKVFKVLNKKNGQKAAVKILDPIHDIDEEIEAGYNILKALSDHPNVVRFYGIYFKKDKVNGDKLWLVLELCSGGSVTDLVKGFLKRGERMSEPLIAYILHEALMGLQHLHNNKTIHRDVKGNNILLTTEGGVKLVDFGVSAQLTSTRHRRNTSVGTPFWMAPEVIACEQQLDTTYDARCDTWSLGITAIELGDGDPPLADLHPMRALFKIPRSDD
-
分子量
54 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYO3A, a member of the myosin superfamily, is primarily expressed in the inner ear, where it plays a crucial role in auditory signal transduction and the development of hair cells. Research into MYO3A has gained momentum due to its implications in various auditory disorders, including non-syndromic hearing loss. Understanding this protein's function and mechanism is vital for developing targeted therapies and interventions for individuals affected by such conditions. Recent studies have focused on the recombinant production of MYO3A, aiming to elucidate its structural and functional properties. This reconstitution allows researchers to explore the protein's interactions with actin filaments, investigate its role in cellular dynamics, and assess its potential as a therapeutic target. Additionally, the ability to produce MYO3A recombinantly paves the way for high-throughput screening of small molecules or compounds that could enhance or inhibit its activity, offering new insights into the treatment of hearing impairments. As the field of molecular biology evolves, harnessing techniques such as CRISPR and advanced protein engineering may further unravel the complexities surrounding MYO3A, making it a focal point of research in auditory biology and regenerative medicine.
